Susquehanna International Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-127,313
Closed -$25K 11179
2019
Q1
$25K Buy
127,313
+94,268
+285% +$20.9K ﹤0.01% 8572
2018
Q4
$23K Buy
33,045
+21,806
+194% +$24.4K ﹤0.01% 8663
2018
Q3
$14K Buy
+11,239
New +$12.6K ﹤0.01% 9028
2018
Q2
Sell
-31,338
Closed -$63K 10813
2018
Q1
$63K Buy
31,338
+17,824
+132% +$33.5K ﹤0.01% 8890
2017
Q4
$16K Sell
13,514
-17,329
-56% -$23.7K ﹤0.01% 9092
2017
Q3
$39K Sell
30,843
-32,400
-51% -$41.4K ﹤0.01% 8583
2017
Q2
$84K Buy
63,243
+27,331
+76% +$39.5K ﹤0.01% 8761
2017
Q1
$67K Sell
35,912
-32,924
-48% -$149K ﹤0.01% 8527
2016
Q4
$357K Buy
+68,836
New +$362K ﹤0.01% 7637
2015
Q3
Sell
-15,424
Closed -$120K 10498
2015
Q2
$95K Sell
15,424
-35,792
-70% -$277K ﹤0.01% 9693
2015
Q1
$412K Buy
51,216
+38,082
+290% +$287K ﹤0.01% 7445
2014
Q4
$66K Buy
+13,134
New +$64.9K ﹤0.01% 9306
2014
Q2
Sell
-21,075
Closed -$149K 10260
2014
Q1
$148K Buy
+21,075
New +$165K ﹤0.01% 8417

Other funds holding GNMX

Susquehanna International Group's GNMX Position: Q2 2019 in Review

Susquehanna International Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2019, closing a stake of 127,313 shares — an estimated $25K sold.

Susquehanna International Group first reported a position in GNMX in Q1 2014 and held it in 13 quarters. The position peaked at $412K in Q1 2015. 29 funds tracked by Wall St. Rank hold GNMX as of Q2 2019.

  • Susquehanna International Group reported no remaining Aevi Genomic Medicine Inc position as of Q2 2019 after selling out during the quarter.
  • Susquehanna International Group sold 127,313 Aevi Genomic Medicine Inc shares in Q2 2019, an estimated $25K.
  • Susquehanna International Group first reported a position in Aevi Genomic Medicine Inc in Q1 2014 and held it in 13 quarters.
  • Susquehanna International Group's Aevi Genomic Medicine Inc position peaked at $412K in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2019.

Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.